Abstract

CALDERA, David J  and  BURNEO, Jorge G. Juvenile myoclonic epilepsy. Rev Neuropsiquiatr [online]. 2018, vol.81, n.4, pp.250-256. ISSN 0034-8597.  http://dx.doi.org/10.20453/rnp.v81i4.3439.

Juvenile Myoclonic Epilepsy (JME) is a generalized type of epilepsy characterized by the occurrence of myoclonic seizures and, less frequently, of generalized tonic-clonic seizures and absences. The onset usually occurs during puberty or adolescence. Worldwide, it is estimated that there is a new case of JME per year for every 1000-2000 people. Its diagnosis is fundamentally clinical, corroborated by EEG tests. The first drug of choice for the treatment of JME is still valproic acid; however, lamotrigine and levetiracetam have shown efficacious results for the control of JME, used as monotherapy or polytherapy with topiramate as a coadyuvant for the control of generalized tonic- clinic seizure.

Keywords : Epilepsy; juvenile; myoclonic epilepsy; myoclonus; JME.

        · abstract in Spanish     · text in Spanish     · Spanish ( pdf )